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Endocarditis due to Mycobacterium fortuitum complex is a rare entity generally linked to
the hospital environment. Only 18 cases have been published since 1966. Here we present
a case of a female who developed an endocarditis due to Mycobacterium chelonae after
valve replacement as well as a review of the literature. The course of this kind of
endocarditis is generally subacute and the outcome is usually fatal. Blood cultures were
positive in 75% of cases of metallic valve endocarditis, versus 20% in bioprostheses. The
treatment must include antibiotics that have shown activity against these mycobacteria,
such as amikacin, imipenem, cefoxitin, ﬂuorinated quinolones andmacrolides (especially
clarithromycin). Surgical removal is recommended. Although the prognosis for the
patient is poor, we should expect better outcomes with the use of new antibiotic
regimens.
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Non-tuberculous mycobacteria are generally divi-
ded into four groups, based on in vitro growth
characteristics. The Mycobacterium fortuitum com-
plex contains the most important pathogens of
group IV of the Runyon classiﬁcation [1] and they
have been described as causative agents of skin
abscesses, pulmonary infection, meningitis, osteo-
myelitis, postsurgical infections, cervical lympha-
denitis and keratitis [2]. This paper describes a case
of endocarditis caused by this type of mycobacter-
ium and reviews the literature on this topic.
CASE DESCRIPTION
A 57-year-old woman had rheumatic fever in
childhood with involvement of the mitral, aortic
and tricuspid valves; she had received mitral and
aortic valve replacement 7 months prior to her cur-
rent admission. She was admitted to our hospital
because of a transient cerebrovascular accident
and congestiveheart failure. Transthoracic echocar-
diography was performed, revealing vegetations
on the mitral and aortic valves. Staphylococcus
epidermidis grew in only one set of three blood
cultures.
Both bioprostheses were replaced by two new
mechanical prostheses, and antibiotic therapy
with vancomycin was started. Cultures of the
two valves were negative. Control blood cultures
were negative, but 4 weeks later the patient suf-
fered a deterioration of her clinical status, with
fever, severe dyspnea and clinical and echocardio-
graphic signs of mitral and aortic insufﬁciency.
The mitral and aortic prostheses were replaced by
new mitral mechanical prostheses and an aortic
homograft. During surgery, the mitroaortic annu-
lus was found to be greatly damaged, and sternal
osteomyelitis was also observed. A Gram stain
was negative, but an auramine–rhodamine stain
of the valve showed acid–alcohol-resistant bacilli.
Cultures were made in Lowenstein–Jensen med-
ium with and without sodium pyruvate (Difco
Laboratories, Becton Dickinson, Sparts, MD,
USA) from valve and sternum, and blood cultures
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were performed in 13A bottles from the BACTEC
460 radiometric system (Becton Dickinson SA).
Growth of Mycobacterium chelonae was obtained
in all samples apart from blood in 6–7days. The
strain was identiﬁed asM. chelonae subsp. chelonae
by biochemical and chromatographic techniques.
The patient was started on therapy with imipenem
(500mg/6 h) and amikacin (1 g/12 h). From the
ﬁrst day after surgery, she developed fever. Initial
transesophageal echocardiography (TEE) revealed
normal function of the prosthesis. She continued to
be febrile despite antibiotics, developing hemody-
namic instability and oliguria. A new TEE showed
severe mitral insufﬁciency and mitral paravalvu-
lar leakage. The patient died as a result of multi-
organ failure on the 64th day after admission.
Permission for autopsy was not obtained.
DISCUSSION
A review of the literature from 1966 to 2000 was
performed using the keywords ‘endocarditis’,
‘chelonae’ and ‘fortuitum’. The literature reveals
18 cases, apart from our own, whose main char-
acteristics are described in Table 1.
Twelve of the patients were men, and seven
were women. The mean age was 45 years (range:
20–74). Affected valves were native in four cases.
Of those with prosthetic valves, six were biological
and nine weremechanical. Inmost cases, the aortic
valve was the affected one (10 cases), followed by
the mitral valve (seven cases). Only one patient
developed mitroaortic infection, and one patient
had tricuspid involvement. Transthoracic echocar-
diography was performed in six cases (two of
them with M-mode), being negative for endocar-
ditis in two cases; transesophageal echo was per-
formed in four cases, revealing paravalvular leak
in one patient, abscess in two, and mobile vegeta-
tions in three. When the valve was removed, all
cases except one[ 3] had positive culture for myco-
bacteria. Blood cultures were positive in 11 cases
(68%): M. chelonae was cultured in four cases and
M. fortuitum in six, and there was one case inwhich
the type of rapidly growing potential pathogen
was not identiﬁed [4].
Apart from blood, mycobacteria were isolated
from other biological samples: three from the ster-
notomy wound, one from the lung, one from a
lumbar vertebra, one from the urinary catheter,
and one from cerebrospinal ﬂuid. Eight of 18
patients underwent valve replacement (Table 1).
Multiple antibiotic regimens were used: the most
common were amikacin (nine cases) and isoniazid
(seven cases). In 16 cases, the patients died (88%).
M. fortuitum complex endocarditis is a rare
entity [2]. Prosthetic valve endocarditis represents
80% of the cases. This fact would suggest a noso-
comial source of infection, as would the fact that
this type of mycobacterium has been isolated from
cardioplegia solutions [5], water systems in oper-
ating rooms [3], preoperative sterilization ﬂuids
[6] and valve preservation solutions [7]. On the
other hand, there are four cases of native valve
endocarditis, which raises once again fundamental
questions concerning the pathogenic mechanism
of infection. In these cases, invasive procedures
were involved: hemodialysis, urethral dilatations,
balloon valvulotomy and intravenous drug
administration.
The course of disease seems to be subacute, with
a mean interval of 12weeks between infection and
onset of symptoms, without differences between
biological and mechanical valves. It is noteworthy
that blood cultures yielded positive results in 75%
of the endocarditis cases affecting metallic valves,
but in only 20% of cases involving bioprostheses
and in 100% of cases of native endocarditis (only
four cases). When mycobacteria were isolated
from other biological sources, the blood cultures
were positive in all cases except one (present case),
which could be interpreted as hematogenous dis-
semination with systemic spread of the organism
[4], or endocardial infection from other primary
sites of infection, as may be thought to occur in
cases of sternal wound infection [8,9].
Although the resistance in vitro of these myco-
bacteria to antituberculous drugs is well known
[10], these were the drugs most frequently used in
cases of M. fortuitum complex endocarditis before
the 1990s. Since then, the use of such drugs has
declined, in favor of amikacin. There are just a few
cases inwhich patients are treatedwithmacrolides
or ﬂuorinated quinolones, drugs which have also
shown activity against these mycobacteria [11,12].
Possibly, antibiotic treatment should include a
combination of those antibiotics that have shown
in vitro efﬁcacy against the M. fortuitum complex:
amikacin, imipenem, cefoxitin, ﬂuorinated quino-
lones andmacrolides (specially clarithromycin). In
fact, it is of note that those patients who survived
received one or another of these drugs [11,13].
Patients with endocarditis caused by these
organisms should be considered candidates for
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early surgical intervention and removal of the
infected material [8,11]. Nevertheless, our data
show that surgery was only performed in 37%
of the cases, perhaps due to the poor clinical state
of the patient at diagnosis. However, two patients
survived in the absence of surgical treatment.
It should be emphasized that 85% of the patients
who developed endocarditis due to atypical myco-
bacteria died. We must consider these organisms
in endocarditis after valve replacement with nega-
tive blood cultures. Early diagnosis and the use of
new regimens of antibiotic therapy can improve
the survival rate of these patients.
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